MSD’s Keytruda-Padcev combo secures EC approval for MIBC

The EC has approved MSD's Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC). The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas. The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. Credit: Antonio Marca / Shutterstock.com. The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC). The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. LOA and…

Salong Debbarma · 2026-06-25

The EC has approved MSD's Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).

Source: Pharmaceutical Technology